ADAM17 and ovarian cancer: For ovarian cancer it has been demonstrated that an ADAM17-antibody reduces tumor growth in a xenograft model [30]; using the same antibody we confirmed the ADAM17 selectivity of AREG-shedding in our ovarian cancer cells.